3 Supercharged Growth Stocks to Buy and Hold Into the 2030s

Amazon reported Q3 revenue of $180.2B (+13% YoY) with AWS up 20% and net income of $21.2B (+38% YoY); management projects $125B in 2025 capex, is expanding AI efforts (Trainium/Inferentia) and sees advertising rising past $60B in 2025 with potential to approach $100B, while one-time items (FTC settlement $2.5B, severance $1.8B) masked higher adjusted operating income of $21.7B. Vertex posted Q3 revenue >$3B (+11% YoY) and $1.1B net income, holds ~$12B cash, is rolling out gene-editing therapy Casgevy and Journavx (300k prescriptions), and has multiple late-stage candidates (inaxaplin, povetacicept, zimislecel) that could produce filings/approvals in 2026–2027. TJX beat Q3 fiscal 2026 estimates with EPS $1.28 on $15.1B revenue (+12% and +7% YoY), returned $1.1B to shareholders, operates an expanding store footprint (5,191 stores with a 7,000-store long-term target) and benefits from resilient off-price consumer demand.

Analysis

Market structure: Amazon, Vertex (VRTX), and TJX are clear beneficiaries — AWS (≈30% infra share) and ad growth (>$60B in 2025, potential path to ~$100B) shift profit pools toward platforms with first‑party data and scale. Traditional full‑price retailers, legacy cloud infrastructure vendors and small biotechs without late‑stage assets are the direct losers as pricing power concentrates and capital flows to AI/data center capex (AMZN capex guide ~$125B in 2025) and gene/ cell therapy manufacturing.

Risk assessment: Key tail risks are regulatory (FTC/antitrust for AMZN; reimbursement and FDA negative interim reads for VRTX), technology execution (Trainium/Inferentia vs NVIDIA), and manufacturing scale for cell/gene therapies. Immediate (days) risks are earnings/clinical readout volatility; short term (weeks–months) hinge on FDA interim analyses (VRTX 1H‑2026 targets) and AWS quarterly growth; long term (years) on store rollouts (TJX to 7,000 stores) and successful automation savings realization (~$4B target).

Trade implications: Favor concentrated, sized exposures with defined stops: tactical longs in AMZN (capture ad + AWS re‑rate), VRTX ahead of filings (binary upside) and TJX as defensive retail growth. Use pair trades (long TJX vs short Macy’s KMB/M? or M) and option structures to hedge binary outcomes (long VRTX calls, sell covered calls on TJX). Cross‑asset: heavy tech capex supports copper/energy demand and may steepen credit spreads for lower‑grade corporates; expect higher implied vol in biotech around FDA milestones.

Contrarian angles: Consensus may underweight execution risk in AMZN’s massive capex — if Trainium/Inferentia fail to materially reduce AI running costs, margins could disappoint and NVDA dominance persist. VRTX may be over‑valued on successful launch narratives; failure or slower reimbursement would compress multiples sharply. TJX’s physical expansion is durable but cyclical: a macro slowdown that raises unemployment materially (>200bp) could pull discretionary traffic and expose overexpansion.

Key Decisions for Investors

• Establish a 2–4% portfolio long position in AMZN over the next 2–6 weeks (scale in 25% tranches). Rationale: AWS + ads re‑rating; trim 30% of the position on a +40% move or cut to half size if two consecutive quarters show AWS y/y growth <12% or ad revenue deceleration >300 bps vs guidance.
• Initiate a 1–2% long in VRTX using Jan 2027 LEAP calls (~12–18 month tenor) sized so max premium = 1–2% portfolio value. Rationale: binary upside from planned 1H‑2026 accelerated filing catalysts (inaxaplin/povetacicept); exit and close calls immediately if interim analysis misses primary endpoints or FDA issues clinical hold.
• Buy 1–2% allocation to TJX (T.J. Maxx) with simultaneous sale of 6‑month OTM calls ~8–10% above purchase to generate yield. Rationale: durable off‑price moat and rollout runway to 7,000 stores; unwind if comp‑store sales decline y/y for two quarters or gross margin compresses >150 bps.
• Execute a pair trade: long 1% TJX vs short 1% Macy’s (M) or Kohl’s (KSS) for 6–12 months to express off‑price resilience vs department store weakness. Close if spread narrows <50% of entry or macro unemployment falls >100 bps improving full‑price retail trends.
• Use options hedge: buy VRTX 6–9 month calendar calls (roll into LEAP on positive signs) rather than outright stock for limited downside; cap total options premium risk at 1–1.5% portfolio and monitor FDA calendar closely (position size increase only after positive interim readouts).